EP1252165A1 - Isoxazolopyrimidinone und ihre verwendung - Google Patents
Isoxazolopyrimidinone und ihre verwendungInfo
- Publication number
- EP1252165A1 EP1252165A1 EP00987389A EP00987389A EP1252165A1 EP 1252165 A1 EP1252165 A1 EP 1252165A1 EP 00987389 A EP00987389 A EP 00987389A EP 00987389 A EP00987389 A EP 00987389A EP 1252165 A1 EP1252165 A1 EP 1252165A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- diseases
- general formula
- medicament
- different
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to new isoxazolopyrimidinones, processes for their preparation and their use as medicaments, in particular as inhibitors of cGMP-metabolizing phosphodiesterases.
- the compounds according to the invention are potent inhibitors of cyclic
- cGMP -PDE's Guanos n 3 ', 5'-monophophate metabolizing phosphodiesterases
- An increase in the cGMP concentration can lead to curative, anti-aggregatory, anti-thrombotic, anti-proliferative, anti-vasospastic, vasodilating, natriuretic and diuretic effects. It can affect short or long-term modulation of vascular and cardiac inotropy, cardiac rhythm and cardiac conduction (J.C. Stoclet, T. Keravis, N. Komas and C. Kugnier, Exp. Opin.
- R 1 represents (C 3 -C 8 ) cycloalkyl or straight-chain or branched alkyl having up to 4 carbon atoms
- R 2 and R 7 are the same or different and are hydrogen or straight-chain or branched alkyl having up to 4 carbon atoms,
- R 3 , R 4 , R 5 and R 6 are the same or different and are hydrogen, a 5- to 6-membered aromatic heterocycle with up to 3 heteroatoms from the series S, N and / or O or aryl with 6 to 10 carbon atoms , where the ring systems are optionally substituted up to three times, identically or differently, by hydroxy, halogen, (C Cs) - alkyl or (-C-C 6 ) alkoxy, or
- R 3 , R 4 , R 5 and R 6 are identical or different and are (C 1 -C 6) -alkyl, which is optionally substituted by aryl having 6 to 10 carbon atoms and in turn up to 3 times, identical or different, by (-C ⁇ alkyl, (-C ⁇ alkoxy, hydroxy or halogen may be substituted,
- R 8 denotes hydrogen or (-C ⁇ alkyl, which is optionally substituted by hydroxy
- R 9 represents hydrogen or hydroxy
- the compounds according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or do not behave like image and mirror image (diastereomers).
- the invention relates to both the enantiomers or diastereomers or their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
- the substances according to the invention can also be present as salts. Physiologically acceptable salts are preferred in the context of the invention.
- Physiologically acceptable salts can be salts of the compounds according to the invention with inorganic or organic acids.
- Salts with inorganic acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid, or methanesulfonic acid, ethanesulfonic acid are preferred , Phenylsulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid.
- Physiologically acceptable salts can also be metal or ammonium salts of the compounds according to the invention.
- Sodium, potassium, magnesium or calcium salts and also ammonium salts derived from ammonia, or organic amines, such as ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, Ethylenediamine or 2-phenylethylamine.
- Cycloalkyl stands for cyclopropyl, cyclopentyl, cyclobutyl, cyclohexyl, cycloheptyl or cyclooctyl. May be mentioned: cyclopropyl, cyclopentyl and
- (C ⁇ - gVAryl stands for an aromatic radical with 6 to 10 carbon atoms.
- Preferred aryl radicals are phenyl and naphthyl.
- (C j -C ⁇ alkyl stands for a straight-chain or branched alkyl radical having 1 to 6 carbon atoms. Examples include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl and n-Hexyl.
- a straight-chain or branched alkyl radical having 1 to 4 carbon atoms is preferred.
- a straight-chain or branched alkyl radical having 1 to 3 carbon atoms is particularly preferred.
- (C 1 C 6 ) alkoxy represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms.
- Examples include; Methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, ter-butoxy, n-pentoxy and n-hexoxy.
- a straight-chain or branched alkoxy radical having 1 to 4 carbon atoms is preferred.
- a straight-chain or branched alkoxy radical having 1 to 3 carbon atoms is particularly preferred.
- Halogen generally represents fluorine, chlorine, bromine and iodine. Fluorine, chlorine and bromine are preferred. Fluorine and chlorine are particularly preferred.
- a 5- to 6-membered aromatic heterocycle with up to 3 heteroatoms from the series S, O and / or N is, for example, pyridyl, pyrimidyl, pyridazinyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl or imidazolyl.
- Pyridyl, pyrimidyl, pyridazinyl, furyl and thienyl are preferred.
- R 1 for (C 3 -C 6 ) cycloalkyl or for. is n-propyl
- R, 2 and j ⁇ R.7 are the same or different and are hydrogen, methyl or ethyl
- R 3 , R 4 , R 5 and R 6 are the same or different and are hydrogen, pyridyl, pyrimidyl, pyridazinyl, furyl, tmidazolyl, thienyl, pyrryl or phenyl
- the ring systems optionally up to 2 times, identical or different, by Hydroxy, fluorine, chlorine, (-G -alkyl or (-CC) alkoxy are substituted
- R 3 , R 4 , R 5 and R 6 are the same or different and are (CC ⁇ -alkyl, which is optionally substituted by phenyl, which in turn is up to 2 times the same or different, by (dC ⁇ -alkoxy, fluorine or chlorine can be substituted,
- R 8 denotes hydrogen or (-C ⁇ alkyl, which is optionally substituted by hydroxy
- R 9 denotes hydroxy
- R 1 represents cyclopentyl or n-propyl
- R 2 and R 7 are the same or different and are methyl or ethyl
- R 3 , R 4 , R 5 and R 6 are identical or different and represent hydrogen, pyridyl or phenyl, the ring systems optionally being substituted up to 2 times, identical or different, by fluorine, methoxy or ethoxy,
- R 3 , R 4 , R 5 and R 6 are identical or different and are (C 1 -C 3 ) -alkyl, which is optionally substituted by phenyl, which in turn is up to 2-fold, identical or different, by methoxy or ethoxy is substituted,
- R > s is hydrogen or (-C-C3) alkyl or a radical of the formula
- - (CH 2 ) 2 means -OH
- R, 9 denotes hydroxy
- R 1 has the meaning given above
- R 2 and R 7 have the meaning given above
- a 'and R 1 have the meaning given above,
- a 'and R 1 have the meaning given above,
- a 'and R 1 have the meaning given above,
- R 10 and R 11 include the scope of R 3 , R 4 , R 5 and R 6 given above, implements.
- organic solvents which do not change under the reaction conditions are suitable as solvents for the individual steps.
- solvents preferably include ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fuctions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethane, trichlorethylene or chlorine or chlorine or chlorine thylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the solvents mentioned.
- the reaction temperatures can generally vary within a substantial range. Generally one works in a range from -20 ° C to 200 ° C, preferably from 0 ° C to 70 ° C.
- the process steps according to the invention are generally carried out at normal pressure. However, it is also possible to carry out at overpressure or at underpressure (e.g. in a range from 0.5 to 5 bar).
- the reactions can take place, for example, in a temperature range from 0 ° C. to room temperature and at normal pressure.
- the compounds of the general formula (D are new and can be prepared (for example analogously to Gazz. Chim. Ital. 97, 1967, 25-33) by using compounds of the general formula (VD)
- R 1 has the meaning given above
- R 1 has the meaning given above, convicted
- R 1 has the meaning given above
- R 1 has the meaning given above
- R 1 has the meaning given above
- the compounds of the general formula (IV) are not known.
- the compounds of the general formula (V) are not known.
- the compounds of the general formula (T) according to the invention show an unforeseeable, valuable spectrum of pharmacological action.
- the compounds according to the invention enhance the action of substances such as EDRF (endothelium derived relaxing factor), ANP (atrial natriuretic peptide), nitrovasodilators and all other substances which increase the cGMP concentration in a manner other than phosphodiesterase inhibitors.
- EDRF endothelium derived relaxing factor
- ANP atrial natriuretic peptide
- nitrovasodilators all other substances which increase the cGMP concentration in a manner other than phosphodiesterase inhibitors.
- the compounds of the general formula (T) according to the invention are therefore suitable for the prophylaxis and / or treatment of diseases in which an increase in the cGMP concentration is healing, ie diseases which are related to cGMP-regulated processes (in English usually simply as 'cGMP-related diseases'). These include cardiovascular diseases, diseases of the genitourinary system and cerebrovascular explanations.
- cardiac diseases in the sense of the present invention includes diseases such as, for example, high blood pressure, neuronal hypertension, stable and unstable angina, peripheral and cardiac vascular diseases, arrhythmias, thromboembolic diseases and ischemia such as myocardial infarction, stroke, transitory and ischemic attacks pectoris, peripheral circulatory disorders, prevention of restenosis after thrombolysis therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary angioplasty (PTCA) and bypass.
- PTA percutaneous transluminal angioplasty
- PTCA percutaneous transluminal coronary angioplasty
- the compounds of the general formula (I) according to the invention can also be of importance for cerebrovascular diseases. These include, for example, cerebral ischemia, stroke, reperfusion damage, brain trauma, edema, cerebral thrombosis, dementia and Alzheimer's disease.
- the relaxing effect on smooth muscles makes them suitable for the treatment of diseases of the genitourinary system such as prostate hypertrophy, incontinence and in particular for the treatment of erectile dysfunction and female sexual
- PDE phosphorus diesterases
- the cGMP-stimulable PDE ⁇ , the cGMP-inhibitable PDE I and the cAMP-specific PDE IV were isolated from either porcine or bovine myocardium.
- Ca + -calmodulin stimulable PDE I was from porcine aorta, Schwemehi or preferably isolated from bovine aorta.
- the c-GMP specific PDE V was obtained from pig small intestine, pig aorta, human platelets and preferably from bovine aorta.
- the purification was carried out by anion exchange chromatography on MonoQ R Pharmacia essentially according to the method of M. Hoey and Miles D. Houslay, Biochemical Pharmacology, Vol. 40, 193-202 (1990) and C. Lugman et al.
- the enzyme activity is determined in a test batch of 100 ⁇ l in 20 mM Tris / HCl buffer pH 7.5, which contains 5 mM MgCl 2 , 0.1 mg / ml bovine serum albumin and contains either 800 Bq 3 HcAMP or 3 HcGMP.
- the final concentration of the corresponding nucleotides is 10 6 mol / 1.
- the reaction is started by adding the enzyme, the amount of enzyme is such that about 50% of the substrate is converted during the incubation period of 30 min.
- 3 HcAMP is used as substrate and 10 "6 mol / l unlabeled cGMP is added to the batch.
- the inhibition of one or more phosphodiesterases of this type leads to an increase in the cGMP concentration. This makes the connections interesting sant for all therapies in which an increase in the cGMP concentration can be assumed to be beneficial.
- the new active ingredients and their physiologically acceptable salts can be converted into the customary formulations in a known manner, such as tablets, dragées, pills, granules, aerosols,
- the therapeutically active compound should in each case be present in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. H. in amounts sufficient to achieve the dosage range indicated.
- the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, z. B. in the case of the use of water as a diluent, optionally organic solvents as auxiliary
- solvents can be used.
- the application is carried out in the customary manner, preferably orally, transdermally or parenterally, for example peringuically, buccally, intravenously, nasally, rectally or by inhalation.
- parenteral administration such as nasal, buccal, or inhalative via mucous membranes, a dosage of 0.001 mg / kg -0.5 mg kg is advisable.
- the compounds according to the invention are also suitable for use in veterinary medicine.
- the compounds or their non-toxic salts can be administered in a suitable formulation in accordance with general veterinary practices.
- the veterinarian can determine the type of application and the dosage according to the type of animal to be treated.
- Example VI are introduced with a catalytic amount of 4-N, N-dimethylaminopyridine (DMAP) in 2.0 ml of pyridine. 553.9 mg (3.0 mmol) of 2-ethoxybenzoic acid chloride are added and the mixture is stirred at 60 ° C. for 5 h before a further 277 mg of 2-ethoxybenzoic acid chloride are added. After an additional 5 h at 60 ° C., the reaction mixture is taken up in dichloromethane and washed twice with saturated
- DMAP 4-N, N-dimethylaminopyridine
- Example IX 40 mg (0.08 mmol) of the sulfonic acid chloride Example IX are dissolved in 1 ml of dichloromethane and 20 mg (0.24 mmol) of N-methylpiperazine and a spatula tip of DMAP are added at 0 ° C. The reaction mixture is stirred for 16 hours at room temperature. After dilution with dichloromethane, the mixture is extracted with ammonium chloride solution, dried over sodium sulfate and the solvent in
- Example 4 The preparation is carried out analogously to Example 3, starting from 40 mg (0.08 mmol)) of the sulfonic acid chloride from Example XD and 30 mg (0.24 mmol) of 4-methoxy-3-fluoro-aniline.
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19962925 | 1999-12-24 | ||
DE1999162925 DE19962925A1 (de) | 1999-12-24 | 1999-12-24 | Neue Isoxazolopyrimidinone und ihre Verwendung |
DE2000103287 DE10003287A1 (de) | 2000-01-27 | 2000-01-27 | Neue Isoxazolopyrimidinone und ihre Verwendung |
DE10003287 | 2000-01-27 | ||
PCT/EP2000/012562 WO2001047934A1 (de) | 1999-12-24 | 2000-12-12 | Isoxazolopyrimidinone und ihre verwendung |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1252165A1 true EP1252165A1 (de) | 2002-10-30 |
Family
ID=26004036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00987389A Withdrawn EP1252165A1 (de) | 1999-12-24 | 2000-12-12 | Isoxazolopyrimidinone und ihre verwendung |
Country Status (6)
Country | Link |
---|---|
US (1) | US6777416B2 (de) |
EP (1) | EP1252165A1 (de) |
JP (1) | JP2003519153A (de) |
AU (1) | AU2365001A (de) |
CA (1) | CA2395418A1 (de) |
WO (1) | WO2001047934A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
ES2233685T3 (es) * | 2000-08-01 | 2005-06-16 | Bayer Healthcare Ag | Inhibidores selectivos de pde 2 como medicamentos para mejorar la percepcion. |
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666908A (en) * | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
US5250534A (en) * | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
ATE163647T1 (de) | 1993-08-26 | 1998-03-15 | Ono Pharmaceutical Co | 4-aminopyrimidin derivate |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
ZA969888B (en) | 1995-11-28 | 1997-05-26 | Schering Corp | 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
BR9812785A (pt) | 1997-11-12 | 2000-10-10 | Bayer Ag | "imidazotriazinonas 2-fenil-substituìdas como inibidores de fosfodiesterase" |
DE19838705A1 (de) | 1998-08-26 | 2000-03-02 | Bayer Ag | Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one |
-
2000
- 2000-12-12 US US10/149,659 patent/US6777416B2/en not_active Expired - Fee Related
- 2000-12-12 CA CA002395418A patent/CA2395418A1/en not_active Abandoned
- 2000-12-12 EP EP00987389A patent/EP1252165A1/de not_active Withdrawn
- 2000-12-12 WO PCT/EP2000/012562 patent/WO2001047934A1/de not_active Application Discontinuation
- 2000-12-12 JP JP2001549404A patent/JP2003519153A/ja active Pending
- 2000-12-12 AU AU23650/01A patent/AU2365001A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO0147934A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20030149033A1 (en) | 2003-08-07 |
AU2365001A (en) | 2001-07-09 |
WO2001047934A1 (de) | 2001-07-05 |
CA2395418A1 (en) | 2001-07-05 |
US6777416B2 (en) | 2004-08-17 |
JP2003519153A (ja) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1049695B1 (de) | 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren | |
EP1107968B1 (de) | Dihydro-[1,2,3]triazolo-[4,5-d]pyrimidin-7-on | |
EP1244673A2 (de) | Imidazo[1,3,5]triazinone und ihre verwendung | |
EP1280805B1 (de) | Neue imidazotriazinone und ihre verwendung | |
WO1999067244A1 (de) | 7-alkyl- und cycloalkyl-substituierte imidazotriazinone | |
EP1261609B1 (de) | Triazolotriazinone und ihre verwendung | |
EP0271795A2 (de) | Octahydro-10-oxo-6H-pyridazo [1,2-a] [1,2] diazepin-Derivate, Zwischenprodukte und Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel | |
EP0722943A1 (de) | 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one | |
WO2002064593A1 (de) | 2-alkoxyphenyl-substituierte imidazotriazinone | |
EP1252165A1 (de) | Isoxazolopyrimidinone und ihre verwendung | |
DE19702785A1 (de) | Neue cyclische Harnstoffderivate | |
DE19838300A1 (de) | 9-Dialkylaminopurinon-derivate | |
DE19962925A1 (de) | Neue Isoxazolopyrimidinone und ihre Verwendung | |
DE10003287A1 (de) | Neue Isoxazolopyrimidinone und ihre Verwendung | |
DE19812462A1 (de) | 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid | |
DE19962927A1 (de) | Neue Triazolotriazinone und ihre Verwendung | |
DE19962928A1 (de) | Neue Imidazo[1,3,5]triazinone und ihre Verwendung | |
DE10003296A1 (de) | Neue Triazolotriazinone und ihre Verwendung | |
DE10003323A1 (de) | Neue Imidazo[1,3,5[triazinone und ihre Verwendung | |
DE19750085A1 (de) | 2-Phenyl-substituierte Imidazotriazinone | |
DE19840289A1 (de) | 2-Phenyl-substituierte Imidazotriazinone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020724 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: LAMPE, THOMAS Inventor name: HANING, HELMUT Inventor name: DEMBOWSKY, KLAUS Inventor name: ES-SAYED, MAZEN Inventor name: SCHMIDT, GUNTER Inventor name: BISCHOFF, ERWIN Inventor name: PERZBORN, ELISABETH Inventor name: NIEWOEHNER, ULRICH |
|
17Q | First examination report despatched |
Effective date: 20030917 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BAYER HEALTHCARE AG |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE ES FR GB IT |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 9/00 20060101ALI20060927BHEP Ipc: C07D 498/04 20060101AFI20060927BHEP Ipc: A61K 31/519 20060101ALI20060927BHEP Ipc: A61P 25/00 20060101ALI20060927BHEP |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20070220 |